The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma.

Shwetha H ManjunathAdam David Cohen Simon F LaceyMegan M DavisAlfred L GarfallJ Joseph MelenhorstRussell MaxwellW Tristram ArscottAmit MaityJoshua A JonesJohn P PlastarasEdward A StadtmauerBruce L Levine Carl H JuneMichael C MiloneIma Paydar

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Bridging-RT appeared safe and feasible with CART-BCMA therapy in our r/rMM patients, though larger future studies are needed to draw definitive conclusions.

Keyphrases

end stage renal disease
multiple myeloma
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
stem cells
current status
bone marrow
mesenchymal stem cells